References
- Groll M, Bochtler M, Brandstetter H et al. Molecular machines for protein degradation. Chembiochem 6, 222–256 (2005).
- Varshavsky A. Regulated protein degradation. Trends Biochem. Sci. 30, 283–286 (2005).
- Girao H, Pereira P, Taylor A et al. Subcellular redistribution of components of the ubiquitin–proteasome pathway during lens differentiation and maturation. Invest. Ophthalmol. Vis. Sci. 46, 1386–1392 (2005).
- Brooks P, Fuertes G, Murray RZ et al. Subcellular localization of proteasomes and their regulatory complexes in mammalian cells. Biochem. J. 346, 155–161 (2000).
- Glickman MH, Raveh D. Proteasome plasticity. FEBS Lett. 579, 3214–3223 (2005).
- Cooper EM, Hudson AW, Amos J et al. Biochemical analysis of Angelman syndrome-associated mutations in the E3 ubiquitin ligase E6-associated protein. J. Biol. Chem. 279, 41208–41217 (2004).
- Eriksen JL, Wszolek Z, Petrucelli L. Molecular pathogenesis of Parkinson’s disease. Arch. Neurol. 62, 353–357 (2005).
- Adams J. The development of proteasome inhibitors as anticancer drugs. Cancer Cell 5, 417–421 (2004).
- Groll M, Ditzel L, Lowe J et al. Structure of 20S proteasome from yeast at 2.4 Å resolution. Nature 386, 463–471 (1997).
- Unno M, Mizushima T, Morimoto Y et al. Structure determination of the constitutive 20S proteasome from bovine liver at 2.75 Å resolution. J. Biochem. 131, 171–173 (2002).
- Orlowski M, Wilk S. Catalytic activities of the 20 S proteasome, a multicatalytic proteinase complex. Arch. Biochem. Biophys. 383, 1–16 (2000).
- Forster A, Whitby FG, Hill CP. The pore of activated 20S proteasomes has an ordered 7-fold symmetric conformation. EMBO J. 22, 4356–4364 (2003).
- Osmulski PA, Gaczynska M. Atomic force microscopy reveals two conformations of the 20 S proteasome from fission yeast. J. Biol. Chem. 275, 13171–13174 (2000).
- Osmulski PA, Gaczynska M. Nanoenzymology of the 20S proteasome: proteasomal actions are controlled by the allosteric transition. Biochemistry 41, 7047–7053 (2002).
- Forster A, Masters EI, Whitby FG et al. The 1.9 Å structure of a proteasome–11S activator complex and implications for proteasome–PAN/PA700 interactions. Mol. Cell 18, 589–599 (2005).
- Whitby FG, Masters EI, Kramer L et al. Structural basis for the activation of 20S proteasomes by 11S regulators. Nature 408, 115–120 (2000).
- Liu CW, Corboy MJ, DeMartino GN et al. Endoproteolytic activity of the proteasome. Science 299, 408–411 (2003).
- Kohler A, Cascio P, Leggett DS et al. The axial channel of the proteasome core particle is gated by the Rpt2 ATPase and controls both substrate entry and product release. Mol. Cell 7, 1143–1152 (2001).
- Rock KL, York IA, Saric T et al. Protein degradation and the generation of MHC class I-presented peptides. Adv. Immunol. 80, 1–70 (2002).
- Claverol S, Burlet-Schiltz O, Girbal-Neuhauser E et al. Mapping and structural dissection of human 20 S proteasome using proteomic approaches. Mol. Cell. Proteomics 1, 567–578 (2002).
- Bose S, Stratford FL, Broadfoot KI et al. Phosphorylation of 20S proteasome α subunit C8 (α7) stabilizes the 26S proteasome and plays a role in the regulation of proteasome complexes by γ-interferon. Biochem. J. 378, 177–184 (2004).
- Rivett AJ, Bose S, Brooks P et al. Regulation of proteasome complexes by γ-interferon and phosphorylation. Biochimie 83, 363–366 (2001).
- Lam YA, Lawson TG, Velayutham M et al. A proteasomal ATPase subunit recognizes the polyubiquitin degradation signal. Nature 416, 763–767 (2002).
- Elsasser S, Gali RR, Schwickart M et al. Proteasome subunit Rpn1 binds ubiquitin-like protein domains. Nature Cell. Biol. 4, 725–730 (2002).
- Verma R, Oania R, Graumann J et al. Multiubiquitin chain receptors define a layer of substrate selectivity in the ubiquitin–proteasome system. Cell 118, 99–110 (2004).
- Wendler P, Lehmann A, Janek K et al. The bipartite nuclear localization sequence of Rpn2 is required for nuclear import of proteasomal base complexes via karyopherin αβ and proteasome functions. J. Biol. Chem. 279, 37751–37762 (2004).
- Yen HC, Espiritu C, Chang EC. Rpn5 is a conserved proteasome subunit and required for proper proteasome localization and assembly. J. Biol. Chem. 278, 30669–30676 (2003).
- Guterman A, Glickman MH. Complementary roles for Rpn11 and Ubp6 in deubiquitination and proteolysis by the proteasome. J. Biol. Chem. 279, 1729–1738 (2004).
- Yao T, Cohen RE. A cryptic protease couples deubiquitination and degradation by the proteasome. Nature 419, 403–407 (2002).
- Babbitt SE, Kiss A, Deffenbaugh AE et al. ATP hydrolysis-dependent disassembly of the 26S proteasome is part of the catalytic cycle. Cell 121, 553–565 (2005).
- Rechsteiner M, Hill CP. Mobilizing the proteolytic machine: cell biological roles of proteasome activators and inhibitors. Trends Cell Biol. 15, 27–33 (2005).
- Ortega J, Heymann JB, Kajava AV et al. The axial channel of the 20S proteasome opens upon binding of the PA200 activator. J. Mol. Biol. 346, 1221–1227 (2005).
- Ustrell V, Hoffman L, Pratt G et al. PA200, a nuclear proteasome activator involved in DNA repair. EMBO J. 21, 3516–3525 (2002).
- Schmidt M, Haas W, Crosas B et al. The HEAT repeat protein Blm10 regulates the yeast proteasome by capping the core particle. Nature Struct. Mol. Biol. 12, 294–303 (2005).
- Kisselev AF, Garcia-Calvo M, Overkleeft HS et al. The caspase-like sites of proteasomes, their substrate specificity, new inhibitors and substrates, and allosteric interactions with the trypsin-like sites. J. Biol. Chem. 278, 35869–35877 (2003).
- Myung J, Kim KB, Lindsten K et al. Lack of proteasome active site allostery as revealed by subunit-specific inhibitors. Mol. Cell 7, 411–420 (2001).
- Kisselev AF, Kaganovich D, Goldberg AL. Binding of hydrophobic peptides to several non-catalytic sites promotes peptide hydrolysis by all active sites of 20 S proteasomes – evidence for peptide-induced channel opening in the α-rings. J. Biol. Chem. 277, 22260–22270 (2002).
- Santamaria PG, Finley D, Ballesta JP et al. Rpn6p, a proteasome subunit from Saccharomyces cerevisiae, is essential for the assembly and activity of the 26 S proteasome. J. Biol. Chem. 278, 6687–6695 (2003).
- McCutchen-Maloney SL, Matsuda K, Shimbara N et al. cDNA cloning, expression, and functional characterization of PI31, a proline-rich inhibitor of the proteasome. J. Biol. Chem. 275, 18557–18565 (2000).
- Huang X, Seifert U, Salzmann U et al. The RTP site shared by the HIV-1 Tat protein and the 11S regulator subunit α is crucial for their effects on proteasome function including antigen processing. J. Mol. Biol. 323, 771–782 (2002).
- Shringarpure R, Grune T, Sitte N et al. 4-hydroxynonenal-modified amyloid-β peptide inhibits the proteasome: possible importance in Alzheimer’s disease. Cell. Mol. Life Sci. 57, 1802–1809 (2000).
- Snyder H, Mensah K, Theisler C et al. Aggregated and monomeric α-synuclein bind to the S6´ proteasomal protein and inhibit proteasomal function. J. Biol. Chem. 278, 11753–11759 (2003).
- Zhang X, Turnell AS, Gorbea C et al. The targeting of the proteasomal regulatory subunit S2 by adenovirus E1A causes inhibition of proteasomal activity and increased p53 expression. J. Biol. Chem. 279, 25122–25133 (2004).
- Dantuma NP, Heessen S, Lindsten K et al. Inhibition of proteasomal degradation by the Gly–Ala repeat of Epstein–Barr virus is influenced by the length of the repeat and the strength of the degradation signal. Proc. Natl Acad. Sci. USA 97, 8381–8385 (2000).
- Leonchiks A, Stavropoulou V, Sharipo A et al. Inhibition of ubiquitin-dependent proteolysis by a synthetic glycine–alanine repeat peptide that mimics an inhibitory viral sequence. FEBS Lett. 522, 93–98 (2002).
- Gaczynska M, Osmulski PA. Small-molecule inhibitors of proteasome activity. Methods Mol. Biol. 301, 3–22 (2005).
- Groll M, Huber R. Inhibitors of the eukaryotic 20S proteasome core particle: a structural approach. Biochim. Biophys. Acta 169, 33–44 (2004).
- Rajkumar SV, Richardson PG, Hideshima T et al. Proteasome inhibition as a novel therapeutic target in human cancer. J. Clin. Oncol. 23, 630–639 (2005).
- Groll M, Kim KB, Kairies N et al. Crystal structure of epoxomicin: 20S proteasome reveals a molecular basis for selectivity of α´,β´-epoxyketone proteasome inhibitors. J. Am. Chem. Soc. 122, 1237–1238 (2000).
- Shah IM, Lees KR, Pien CP et al. Early clinical experience with the novel proteasome inhibitor PS-519. Br. J. Clin. Pharmacol. 54, 269–276 (2002).
- Chen D, Daniel KG, Chen MS et al. Dietary flavonoids as proteasome inhibitors and apoptosis inducers in human leukemia cells. Biochem. Pharmacol. 69, 1421–1432 (2005).
- Smith DM, Daniel KG, Wang Z et al. Docking studies and model development of tea polyphenol proteasome inhibitors: applications to rational drug design. Proteins 54, 58–70 (2004).
- Kazi A, Smith DM, Daniel K et al. Potential molecular targets of tea polyphenols in human tumor cells: significance in cancer prevention. In Vivo 16, 397–403 (2002).
- Schmidtke G, Emch S, Groettrup M et al. Evidence for the existence of a non-catalytic modifier site of peptide hydrolysis by the 20 S proteasome. J. Biol. Chem. 275, 22056–22063 (2000).
- Laurent N, de Bouard S, Guillamo JS et al. Effects of the proteasome inhibitor ritonavir on glioma growth in vitro and in vivo. Mol. Cancer Ther. 3, 129–136 (2004).
- Sgadari C, Monini P, Barillari G et al. Use of HIV protease inhibitors to block Kaposi’s sarcoma and tumour growth. Lancet Oncol. 4, 537–547 (2003).
- Zanetti M. Cathelicidins, multifunctional peptides of the innate immunity. J. Leukocyte Biol. 75, 39–48 (2004).
- Gennaro R, Zanetti M, Benincasa M et al. Pro-rich antimicrobial peptides from animals: structure, biological functions and mechanism of action. Curr. Pharm. Des. 8, 763–778 (2002).
- Bao J, Sato K, Li M et al. PR-39 and PR-11 peptides inhibit ischaemia-reperfusion injury by blocking proteasome-mediated IκB α degradation. Am. J. Physiol. Heart Circ. Physiol. 281, H2612–H2618 (2001).
- Gao YH, Lecker S, Post MJ et al. Inhibition of ubiquitin–proteasome pathway-mediated IκB α degradation by a naturally occurring antibacterial peptide. J. Clin. Invest. 106, 439–448 (2000).
- Gaczynska M, Osmulski PA, Gao Y et al. Proline- and arginine-rich peptides constitute a novel class of allosteric inhibitors of proteasome activity. Biochemistry 42, 8663–8670 (2003).
- Paugam A, Creuzet C, Dupouy-Camet J et al. In vitro effects of gliotoxin, a natural proteasome inhibitor, on the infectivity and proteolytic activity of Toxoplasma gondii. Parasitol. Res. 88, 785–787 (2002).
- Kroll M, Arenzana-Seisdedos F, Bachelerie F et al. The secondary fungal metabolite gliotoxin targets proteolytic activities of the proteasome. Chem. Biol. 6, 689–698 (1999).
- Kiyomiya K, Satoh J, Horie H et al. Correlation between nuclear action of anthracycline anticancer agents and their binding affinity to the proteasome. Int. J. Oncol. 21, 1081–1085 (2002).
- Piccinini M, Tazartes O, Mezzatesta C et al. Proteasomes are a target of the antitumour drug vinblastine. Biochem. J. 356, 835–841 (2001).
- Bulteau AL, Lundberg KC, Humphries KM et al. Oxidative modification and inactivation of the proteasome during coronary occlusion/reperfusion. J. Biol. Chem. 276, 30057–30063 (2001).
- Hyun DH, Lee MH, Halliwell B et al. Proteasomal dysfunction induced by 4-hydroxy-2,3-trans-nonenal, an end product of lipid peroxidation: a mechanism contributing to neurodegeneration? J. Neurochem. 83, 360–370 (2002).
- Pajonk F, Scholber J, Fiebich B. Hypericin – an inhibitor of proteasome function. Cancer Chemother. Pharmacol. 55, 439–446 (2005).
- Osmulski PA, Gaczynska M. Ubiquitin and Protein Degradation, Part A. Deshaies RJ (Ed.), Elsevier, Amsterdam, The Netherlands 414–425 (2005).
- Eleuteri AM, Cuccioloni M, Bellesi J et al. Interaction of Hsp90 with 20S proteasome: thermodynamic and kinetic characterization. Proteins 48, 169–177 (2002).
- Dorn IT, Eschrich R, Seemuller E et al. High-resolution AFM-imaging and mechanistic analysis of the 20 S proteasome. J. Mol. Biol. 288, 1027–1036 (1999).
- Hutschenreiter S, Tinazli A, Model K, Tampe R. Two-substrate association with the 20S proteasome at single-molecule level. EMBO J. 23, 2488–2497 (2004).
- Borodovsky A, Ovaa H, Kolli N et al. Chemistry-based functional proteomics reveals novel members of the deubiquitinating enzyme family. Chem. Biol. 9, 1149–1159 (2002).
- Afjehi-Sadat L, Gruber-Olipitz M, Felizardo M et al. Expression of proteasomal proteins in ten different tumor cell lines. Amino Acids 27, 129–140 (2004).
- Kirkpatrick DS, Gerber SA, Gygi SP. The absolute quantification strategy: a general procedure for the quantification of proteins and post-translational modifications. Methods 35, 265–273 (2005).
- Kirkpatrick DS, Denison C, Gygi SP. Weighing in on ubiquitin: the expanding role of mass-spectrometry-based proteomics. Nature Cell. Biol. 7, 750–757 (2005).
- Peng J, Schwartz D, Elias JE et al. A proteomics approach to understanding protein ubiquitination. Nature Biotechnol. 21, 921–926 (2003).
- Verma R, Chen S, Feldman R et al. Proteasomal proteomics: identification of nucleotide-sensitive proteasome-interacting proteins by mass spectrometric analysis of affinity-purified proteasomes. Mol. Biol. Cell 11, 3425–3439 (2000).
- Verma R, Peters NR, D’Onofrio M et al. Ubistatins inhibit proteasome-dependent degradation by binding the ubiquitin chain. Science 306, 117–120 (2004).
- Walz J, Erdmann A, Kania M et al. 26S proteasome structure revealed by three-dimensional electron microscopy. J. Struct. Biol. 121, 19–29 (1998).